根据弗若斯特沙利文数据分析，全球寡核苷酸药物市场规模从2016年0.1亿美元增长至2021年32.5亿美元，年复合增长率高达217.8%。根据Evaluate和BCG分析，2026年全球寡核苷酸市场规模将达到150亿美元（约合人民币1067亿元）。

Custom antibody alternatives business Aptamer said on Tuesday that it has extended its contract with household goods giant ...

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce an extension of its partnership with Unilever to ...

TAGCyx is building a pipeline of Xenoligo aptamers and aptamer–drug conjugates, and is looking for global pharmaceutical partners. DNA or RNA (oligonucleotide) aptamers can have similar ...

Dopamine, a neurotransmitter in our brains, not only regulates our emotions but also serves as a biomarker for the screening ...

YORK-based Aptamer Group has announced further studies with Unilever concerning the use of its Optimer binder technology as active ingredients ...

Aptamer Sciences is a biotech company developing aptamer-based technologies. These short, single-stranded oligonucleotides selectively bind to specific targets, giving them applications in ...

Dopamine is a signaling molecule or neurotransmitter that is known to help control emotions. Dopamine levels are also a ...

In a recent study published in Nature Communications, researchers utilized a comprehensive multi-omics approach, integrating ...

(Alliance News) - Aptamer Group PLC said on Tuesday that it has extended its contract with Unilever PLC for the development of novel Optimer binders for use in deodorant products.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...